Overivew

B-52

Objective

Docetaxel, carboplatin, trastuzumab and pertuzumab with or without estrogen deprivation in treating patients with hormone receptor-positive, HER2-positive operable or locally advanced breast cancer.

Estimated primary completion date: January 2017 (final data collection date for primary outcome measure)

 

Clinical Trial Categories

Oncology

 

Sponsor(s)

National Cancer Institute (NCI)

 

Contact

Research Study Staff at 425-688-5407

(CONTACT FORM HERE)

 

Location

Overlake Medical Center
1035 116th Ave. NE 
Bellevue, WA 98004
Main: 425-688-5000

View all hospital services

Make a gift

Need urgent care?